Shares of Exelixis, Inc. (NASDAQ:EXEL) were down 0.9% on Friday . The company traded as low as $19.68 and last traded at $19.74. Approximately 45,676 shares changed hands during trading, a decline of 98% from the average daily volume of 2,327,762 shares. The stock had previously closed at $19.91.
A number of analysts have recently weighed in on EXEL shares. BMO Capital Markets started coverage on Exelixis in a research report on Friday, February 22nd. They set a “market perform” rating and a $23.00 target price for the company. Cowen reiterated a “buy” rating and set a $29.00 target price on shares of Exelixis in a research report on Tuesday, February 26th. Piper Jaffray Companies reiterated an “overweight” rating and set a $48.00 target price on shares of Exelixis in a research report on Friday, March 1st. Zacks Investment Research upgraded Exelixis from a “strong sell” rating to a “hold” rating in a research report on Monday, March 4th. Finally, ValuEngine upgraded Exelixis from a “sell” rating to a “hold” rating in a research report on Wednesday, March 6th. Six equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $28.88.
The stock has a market cap of $6.01 billion, a price-to-earnings ratio of 13.80, a price-to-earnings-growth ratio of 0.47 and a beta of 1.99. The company has a quick ratio of 7.48, a current ratio of 7.56 and a debt-to-equity ratio of 0.01.
Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.24 earnings per share for the quarter, hitting the consensus estimate of $0.24. Exelixis had a return on equity of 37.21% and a net margin of 75.97%. The business had revenue of $215.49 million during the quarter, compared to the consensus estimate of $206.06 million. During the same period in the prior year, the company earned $0.40 EPS. Exelixis’s revenue for the quarter was up .8% on a year-over-year basis. As a group, equities analysts expect that Exelixis, Inc. will post 0.92 EPS for the current year.
In related news, insider Patrick J. Haley sold 2,700 shares of the company’s stock in a transaction on Tuesday, March 26th. The stock was sold at an average price of $23.47, for a total transaction of $63,369.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director George Poste sold 3,860 shares of the company’s stock in a transaction on Friday, March 29th. The stock was sold at an average price of $23.89, for a total value of $92,215.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 555,930 shares of company stock valued at $12,363,512. 4.50% of the stock is owned by corporate insiders.
Several hedge funds have recently made changes to their positions in EXEL. Icon Wealth Partners LLC bought a new stake in shares of Exelixis during the 1st quarter worth $27,000. FTB Advisors Inc. lifted its position in shares of Exelixis by 312.0% during the 4th quarter. FTB Advisors Inc. now owns 1,545 shares of the biotechnology company’s stock worth $29,000 after buying an additional 1,170 shares during the last quarter. JOYN Advisors Inc. raised its position in Exelixis by 334.2% in the fourth quarter. JOYN Advisors Inc. now owns 1,524 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 1,173 shares during the last quarter. Kore Private Wealth LLC bought a new position in Exelixis in the first quarter valued at about $36,000. Finally, Rockefeller Capital Management L.P. bought a new position in Exelixis in the first quarter valued at about $40,000. Institutional investors and hedge funds own 78.27% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Exelixis (NASDAQ:EXEL) Stock Price Down 0.9%” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2019/06/14/exelixis-nasdaqexel-stock-price-down-0-9.html.
Exelixis Company Profile (NASDAQ:EXEL)
Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
See Also: Closed-End Mutual Funds
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.